MJ Bioscience Terminates Agreement to Acquire Lightning Industries

Friday, 17 August 2018 05:40 PM

MJ Bioscience Corp. (“MJ Bioscience” or the “Company”) announces that it has terminated the acquisition agreement entered into with Lightning Industries Inc. (“Lightning”) and the sole shareholder of Lightning, Domenari Capital, LLC (“Domenari”) on April 24, 2015, as amended May 21, 2015. Under the acquisition agreement, the parties had agreed to terms for MJ Bioscience to acquire 100% of the authorized share capital of Lightning.

 

Terms to the closing of the acquisition agreement required MJ Bioscience to raise a capital investment of $300,000. The Company has been unable to complete the financing due to investor concerns of no secondary market existing to sell the securities of MJ Bioscience. As a result, the parties have mutually agreed to terminate plans for the acquisition.

About Lightning Industries Inc.

 

Lightning is an industrial equipment manufacturer and custom metal fabricator in the natural resources industry. Lighting has 28 years of experience in gas well surface equipment, pneumatics, and electronic safety shutdown systems.

 

About MJ Bioscience Corp.

 

MJ Bioscience is engaged in the research and development of plant technology for the enhanced production of commercial medical marijuana. MJ Bioscience’s principal goal is to target the evaluation and development an efficient system for micro propagation methods that can be reproduced on a commercial scale. MJ Bioscience is also focused on identifying and acquiring related businesses and assets.

 

For further information, please contact:

 

MJ Bioscience Corp.

Marc Branson

Chief Executive Officer and President

Telephone:  604.283.1722

Email:  [email protected]

 

Forward-Looking Information:

 

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of MJ Bioscience.  Forward-looking information is based on certain key expectations and assumptions made by the management of MJ Bioscience, including future plans for acquisitions.  Although MJ Bioscience believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because MJ Bioscience can give no assurance that they will prove to be correct.  Forward-looking statements contained in this press release are made as of the date of this press release.  MJ Bioscience disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.